135 related articles for article (PubMed ID: 36517459)
1. An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.
Miao X; Wu Z; Jiang Y; Liu H; Gong W
Immunology; 2023 Jun; 169(2):157-166. PubMed ID: 36517459
[TBL] [Abstract][Full Text] [Related]
2. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
5. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
6.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract][Full Text] [Related]
7. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
8. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
11. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
12. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
13. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction.
Shi XL; Mancham S; Hansen BE; de Knegt RJ; de Jonge J; van der Laan LJ; Rivadeneira F; Metselaar HJ; Kwekkeboom J
J Hepatol; 2016 Jun; 64(6):1274-82. PubMed ID: 26941095
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts.
Dang N; Waer M; Sprangers B; Lin Y
Am J Transplant; 2021 Jan; 21(1):60-72. PubMed ID: 32506732
[TBL] [Abstract][Full Text] [Related]
16. Blockade or deficiency of PD-L1 expression in intestinal allograft accelerates graft tissue injury in mice.
Matsushima H; Morita-Nakagawa M; Datta S; Pavicic PG; Hamilton TA; Abu-Elmagd K; Fujiki M; Osman M; D'Amico G; Eguchi S; Hashimoto K
Am J Transplant; 2022 Mar; 22(3):955-965. PubMed ID: 34679256
[TBL] [Abstract][Full Text] [Related]
17. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
18. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ
Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
20. α-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8
Wang H; Lin X; Luo Y; Sun S; Tian X; Sun Y; Zhang S; Chen J; Zhang J; Liu X; Liu H; Gong Y; Xie C
Immunotherapy; 2019 Feb; 11(2):101-118. PubMed ID: 30511887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]